RLAY — Relay Therapeutics, Inc.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$1.92B

P/E Ratio

-6.68

Beta

1.62

52-Week Range

1.775-11.49

Dividend Yield

$0.00

CEO

Sanjiv K. Patel

Employees

259

IPO Date

Jul 16, 2020

Exchange

NASDAQ